Company Profile
Passage Bio Stock Price, News & Analysis
Company overview
Business overview
Passage Bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Passage Bio is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Passage Bio follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Passage Bio sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
PASG is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Passage Bio’s catalysts are its rare-CNS gene-therapy programs and any strategic update that clarifies which assets still matter. The company needs stronger clinical clarity.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Passage Bio Announces 1-for-20 Reverse Stock Split
Source: Passage Bio
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.